Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.

Archives of General Psychiatry
Anil K MalhotraJames L Kennedy

Abstract

Second-generation antipsychotics (SGAs) are increasingly used in the treatment of many psychotic and nonpsychotic disorders. Unfortunately, SGAs are often associated with substantial weight gain, with no means to predict which patients are at greatest risk. To identify single-nucleotide polymorphisms associated with antipsychotic drug–induced weight gain. Pharmacogenetic association study. The discovery cohort was from a US general psychiatric hospital. Three additional cohorts were from psychiatric hospitals in the United States and Germany and from a European antipsychotic drug trial. The discovery cohort consisted of 139 pediatric patients undergoing first exposure to SGAs. The 3 additional cohorts consisted of 73, 40, and 92 subjects. Patients in the discovery cohort were treated with SGAs for 12 weeks. Additional cohorts were treated for 6 and 12 weeks. We conducted a genomewide association study assessing weight gain associated with 12 weeks of SGA treatment in patients undergoing first exposure to antipsychotic drugs. We next genotyped 3 independent cohorts of subjects assessed for antipsychotic drug-induced weight gain. Our genome-wide association study yielded 20 single-nucleotide polymorphisms at a single locus exceed...Continue Reading

Associated Clinical Trials

Citations

Mar 19, 2013·European Child & Adolescent Psychiatry·José María Martínez-OrtegaManuel Gurpegui
Jul 10, 2013·Nature Reviews. Genetics·Teri A Manolio
Jun 27, 2013·Translational Psychiatry·E L NurmiUNKNOWN Research Units on Pediatric Psychopharmacology Autism Network
Feb 2, 2013·Current Opinion in Psychiatry·Daniel J MüllerClement C Zai
Dec 18, 2013·Pharmacogenomics·Evangelia Eirini TsermpiniGeorge P Patrinos
Mar 15, 2014·Pharmacogenomics·Eva J BrandlDaniel J Müller
Nov 28, 2013·Pharmacogenomics·Amy C C Kao, Daniel J Müller
Apr 15, 2014·Journal of Child and Adolescent Psychopharmacology·Chadi A CalargeTrudy L Burns
Jun 3, 2014·BMC Medicine·Naji C SalloumJohn R Kelsoe
Aug 21, 2014·Current Psychiatry Reports·Tahireh A Shams, Daniel J Müller
Mar 19, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Aaron JenkinsAmanda J Law
Dec 9, 2014·Biological Psychiatry·Steven P Hamilton
Sep 24, 2013·Current Psychiatry Reports·Robert D Levitan, Barbara Wendland
Feb 20, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Jiamei LianChao Deng
Oct 25, 2013·International Review of Psychiatry·C Anthony AltarDavid Mrazek
Sep 15, 2015·Expert Opinion on Drug Metabolism & Toxicology·Venuja SriretnakumarDaniel J Müller
Nov 12, 2013·Expert Opinion on Drug Safety·Navin V Dargani, Anil K Malhotra
Sep 10, 2013·Child and Adolescent Psychiatric Clinics of North America·Harvey N Kranzler, Sarah D Cohen
Oct 31, 2015·Genes, Brain, and Behavior·Cathy L Barr, Virginia L Misener
Jan 23, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Florence GressierAlessandro Serretti
Sep 24, 2015·Molecular Psychiatry·M A Landek-SalgadoA Sawa
Jun 21, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Licai DongWeihua Yue
Sep 1, 2012·European Eating Disorders Review : the Journal of the Eating Disorders Association·Colleen Stiles-ShieldsDaniel Yohanna
Mar 24, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Donald C GoffSteven G Potkin
Mar 8, 2014·Human Psychopharmacology·Matthew B LanktreeJames L Kennedy
Oct 9, 2015·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Arun K TiwariDaniel J Müller
May 29, 2015·Acta Psychiatrica Scandinavica·P ManuC U Correll
Sep 2, 2015·The Pharmacogenomics Journal·E J BrandlD J Müller
Feb 26, 2014·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Nabilah I ChowdhuryDaniel J Müller
Jun 25, 2015·Pharmacogenomics·Angela M Devlin, Constadina Panagiotopoulos
Jun 5, 2014·Pharmacogenomics·Mark D Brennan
Mar 27, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Paul J Harrison
Sep 6, 2014·Trends in Endocrinology and Metabolism : TEM·Jacob S BallonJeffrey A Lieberman
Jan 13, 2015·European Psychiatry : the Journal of the Association of European Psychiatrists·B ChilizaR Emsley
Aug 8, 2013·The International Journal of Neuropsychopharmacology·Fabian CzerwenskyWerner Steimer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Related Papers

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
Peter R GibsonJason A Tye-Din
© 2021 Meta ULC. All rights reserved